Journals / Van Tıp Dergisi / 2022 / Cilt: 29 - Sayı: 4

Ertapenem Related Neurotoxicity Presented With Visual Halusinations in Chronic Kidney Failure Patient

Kronik Böbrek Yetersizliği Hastasında Görsel Halüsinasyonlar ile Prezente Olan Ertapenem İlişkili Nörotoksisite

Pages
440–444
Publication Date
2022-11-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we wanted to report this issue by presenting our case of visual hallucination observed after the use of ertapenem, even if the dose is adjusted according to the glomerular filtration rate, in a patient with chronic renal failure.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:During the follow-up of patien ts with renal failure, many medications may be required due to the clinical condition and comorbidities.
📊
Key Findings & Data:Even if the dose is adjusted according to the glomerular filtration rate, these side effects can be seen.
💡
Conclusion & Impact:In this study, we wanted to report this issue by presenting our case of visual hallucination observed after the use of ertapenem, even if the dose is adjusted according to the glomerular filtration rate, in a patient with chronic renal failure.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

During the follow-up of patien ts with renal failure, many medications may be required due to the clinical condition and comorbidities. Extreme caution should be exercised during drug use in patients with kidney fail ure. Care should be taken in terms of the nephrotoxic effect of these drugs used or the accumulation of renally excreted drugs in the body and causing toxic effects. One of the most important side effects of carbapenems is neurotoxicity. Although neurological toxicity is most common in the form of epileptic seizures, changes in consciousness and headache can also be seen less frequently. Imipenem is the most frequently mentioned in this respect, similar side effects can be seen due to other carbapenems. Even if the dose is adjusted according to the glomerular filtration rate, these side effects can be seen. Ertapenem-related neurotoxicity is not well-known by clinicians. When the literature is examined, it has been determined that neurotoxicity due to ertapenem is seen more frequently than expected. In this study, we wanted to report this issue by presenting our case of visual hallucination observed after the use of ertapenem, even if the dose is adjusted according to the glomerular filtration rate, in a patient with chronic renal failure.

Özet

Böbrek yetersizliği hastalar ının takibi s ırasında içinde bulunulan klinik durum ve komorbiditeler nedeniyle çok sayıda ilaç kullanılması gerekebilmektedir. Bu hasta grubunda ilaç kullanımı sırasında çok dikkatli olunmalıdır. Kullanılan ilaçların nefrotoksik etkisi veya böbrek yoluyla at ılan ilaçların vücutta birikerek toksik etki yapabilmesi açısından dikkat edilmelidir. Karbapenemlerin en önemli yan etkilerinden biri de nörotoksisitedir. Nöro lojik toksisite en s ık epileptik nöbetler şeklinde olmakla birlikte daha seyrek olarak bilinç durumunda değişiklik ve ba ş ağrısı da görülebilmektedir. Bu yönüyle en çok anılan imipenem olsa da diğer karbapenemlere ba ğlı da benzer yan etkiler görülebilmektedir. Glomerüler filtrasyon hızına göre uygun doz ayarı yapılsa bile bu yan etkiler görülebilir. Ertapenem ilişkili nörotoksisite klinisyenler tarafından çok az bilinmektedir. Literatür incelendiğinde ertapeneme ba ğlı nörotoksisitenin sanıldığından daha sık görüldüğü tespit edilmiştir. Biz de bu çalışmamızda kronik böbrek yetersizliği olan hastada Glomerüler Filtrasyon Hızına göre uygun doz ayarı yapılmış olmasına rağmen ertapenem kullanımı sonrası gözlenen görsel halüsinasyon olgumuzu sunarak bu konuya dikkat çekmeyi amaçladık.

🔖

Cite This Article

Akben, S., Öztürk, İ., Erken, E., Güngör, Ö., Altunören, O. (2022). Ertapenem Related Neurotoxicity Presented With Visual Halusinations in Chronic Kidney Failure Patient. Van Tıp Dergisi, Cilt: 29 - Sayı: 4, 440–444. https://ajindex.com/articles/655535

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Cannon JP, Lee TA, Clark NM, Setlak P & Grim SA. The risk of seizures among the carbapenems: a meta-analysis. J. Antimicrob Chemother 2014; 69(8): 2043-2055
  2. Kara E, Sahin OZ, Ayaz T, Yildirim S, Sahutoglu T, Tufekci A. Ertapenem-induced acute reversible peripheral neuropathy in chronic kidney disease: 3 case reports. Clin Nephrol 2015;84(6):353-357
  3. Adams R, Chopra P, Miranda R, Calderon A. Ertapenem-induced encephalopathy. BMJ Case Rep 2020;13(6):e231875
  4. Van Dijck A, Van Daele W, De Deyn PP. Uremic encephalopathy. Miscellanea on encephalopathies–a second look. InTech; 2012. p.23-38
  5. Mattappalil A, Mergenhagen KA. Neurotoxicity with antimicrobials in the elderly: a review. Clin Ther 2014; 36(11: 1489-1511
  6. Chow KM, Szeto CC, Hui ACF, Li PKT. Mechanisms of antibiotic neurotoxicity in renal failure. Int J Antimicrobial Agents 2004; 23(3): 213-217
  7. Wen MJ, Sung CC, Chau T, Lin SH. Acute prolonged neurotoxicity associated with recommended doses of ertapenem in 2 patients with advanced renal failure. Clin Nephrol 2013; 80(6): 474-478
  8. Shea YF, Mok MYM, Cheng KC, Hon FKS, Chu LW. Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism. Int J Clin Pharm 2013; 35(4): 535-537
  9. Lee KH, Ueng YF, Wu CW, Chou YC, Ng YY, Yang WC. The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients–case reports and literature reviews. J. Clin Pharm Ther 2015; 40(2): 240-244
  10. Burkhardt O, Derendorf H, Welte T. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin. Pharmacother 2007; 8(2): 237-256
  11. Burkhardt O, Hafer C, Langhoff A, Kaever V, Kumar V, Welte T et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009; 24(1): 267-271
  12. El Nekidy WS, Elrefaei H, St. John TJL, Attallah NM, Kablaoui F, Nusair A et al. Ertapenem Neurotoxicity in Hemodialysis Patients—Safe and Effective Dosing Is Still Needed: A Retrospective Study and Literature Review. Ann Pharmacother 2021; 55(1): 52-58.